---
author: All-In Podcast
date: '2026-01-15'
guest: ''
layout: post.njk
source: https://www.youtube.com/watch?v=DBlOJpT9Y1Y
speaker: All-In Podcast
tags:
  - fda-reform
  - biotech-innovation
  - nutrition-science
  - drug-pricing
  - clinical-trials
title: 重构FDA：Marty Makary谈科学透明、效率革命与国民健康
summary: FDA局长Marty Makary详述了其任内的激进改革：通过消除医疗教条、简化临床试验流程（如推行单次关键试验）、重塑膳食指南以及打击药品价格欺诈，旨在恢复公众信任并提升美国生物技术在全球（尤其是针对中国）的竞争力。
insight: ''
draft: true
series: ''
category: tech-trends
area: tech-engineering
project: []
people:
  - Marty Makary
  - Donald Trump
companies_orgs:
  - FDA
  - NIH
  - Johns Hopkins
products_models: []
media_books:
  - The Price We Pay
status: evergreen
---
### 挑战医疗教条：从学术批判到FDA掌舵

**Marty Makary**局长的职业生涯始于对医疗系统深层问题的洞察。作为**约翰霍普金斯大学**（Johns Hopkins）的外科医生和公共卫生专家，他长期关注医疗质量、透明度及价格问题。他曾通过撰写《**我们付出的代价**》（The Price We Pay）一书推动了医院价格透明化的行政命令，并因此进入了决策层的视野。Makary指出，当前的医疗体系深受**医疗家长主义**（Medical Paternalism: 医生或机构代替患者做决定，限制其知情权或选择权）的困扰。

在新冠疫情期间，这种家长主义表现为对非传统观点的压制，例如忽视**自然免疫**（Natural Immunity）以及在缺乏充分数据的情况下强推幼儿口罩令。Makary认为，科学的本质应该是质疑一切，而非设立“神圣不可侵犯”的教条。因此，他上任后的首要任务是将FDA的职能从“审查言论”转向“加速治愈”，通过透明化拒绝信等手段建立问责制，确保机构的决策逻辑对公众开放。

<details>
<summary>Original English Source</summary>
My interest was always in the root causes of our healthcare system problems from quality, transparency, and price. I wrote a book on it that did very well. It took me to the White House where they had read the book, invited me in, and in that first Trump administration, we got the hospital price transparency executive order signed. The sociology of medical dogma is a fascinating historical thing and we still suffer from it—paternalism, suppressing ideas that are not the legacy ideas, sacrificing the basic principles of science to question everything. You saw the worst of that during COVID: cloth masks on toddlers, ignoring natural immunity. My number one priority is not to censor Americans; it's to deliver more cures and meaningful treatments faster and healthier food for children.
</details>

### 效率革命：重塑临床试验与全球生物技术竞赛

面对与中国在生物技术领域的激烈竞争，Makary推动了FDA史上最激进的流程优化。他指出，美国在**临床试验**（Clinical Trials）的审批速度上正面临被超越的风险。为了应对这一挑战，FDA宣布将药物获批所需的**关键性试验**（Pivotal Trials: 用于向监管机构证明药物疗效和安全性的核心三期临床研究）数量从两次默认降为一次，这在保证统计效力的前提下，能为企业节省数亿美元并大幅缩短研发周期。

此外，FDA正在淘汰过时的**动物实验**（Animal Testing）要求，转而采用**计算建模**（Computational Modeling）和**器官芯片**（Organ-on-a-Chip: 在微芯片上模拟人体器官生理功能的生物技术）等现代手段。Makary强调，90%通过动物实验的药物在人体试验中失败，这说明旧有模式不仅存在伦理争议，且效率低下。通过引入**贝叶斯统计**（Bayesian Statistics: 一种基于已知证据动态更新概率的统计方法），FDA旨在实现“持续性试验”，利用AI工具实时监测安全信号，从而在药物证明有效的第一时间将其推向市场。

<details>
<summary>Original English Source</summary>
There is a race and we were losing that race to China and Australia. We need to rethink our entire phase one process. We announced that we are going from a baseline default requirement of two pivotal trials for a drug to one. It saves $100 million to $300 million and shortens the time. We are eliminating a lot of animal testing requirements. 90% of drugs that pass animal studies do not pass safety and efficacy in humans. We have computational modeling and organ on a chip technology now. Can we move to continuous trials? Can we use Bayesian statistical evaluation? Why can't we in real time with AI tools figure out when there's a efficacy established and then call it at that point?
</details>

### 营养学重构：翻转食物金字塔与对抗慢性病

在食品安全领域，Makary发起了“**真实食物**”（RealFood.gov）行动，旨在纠正数十年来被工业界利益腐蚀的营养学教条。他指出，旧有的食物金字塔过度强调**饱和脂肪**的危害，却忽视了**精制碳水化合物**（Refined Carbohydrates）和添加糖对儿童健康的摧毁性影响。目前，美国38%的儿童患有前驱糖尿病或糖尿病，这与长期摄入高糖、低蛋白的饮食习惯直接相关。

FDA正在翻转食物金字塔，将**蛋白质**置于核心地位，并取消了九种人工石油基色素。Makary批评医疗界长期以来将肥胖归咎于意志力问题，而忽视了深加工食品的成瘾性以及**胰岛素抵抗**（Insulin Resistance: 身体细胞对胰岛素反应减弱，导致血糖调节障碍的生理状态）这一慢性病根源。通过重新审视**肠道微生物组**（Microbiome）与自闭症、自身免疫疾病之间的关联，FDA正试图从源头上解决美国的健康危机，而非仅仅依赖药物治疗。

<details>
<summary>Original English Source</summary>
Nutrition science may be one of the most corrupted fields in all of science. It gave us the dogma that we had to focus on saturated fat, ignoring that you replace fats with refined carbohydrates. 60 to 70% of the calories of a child in America today are refined carbohydrates. We have flipped the food pyramid upside down using good science, focusing on the importance of protein. We have drugged our nation's kids at scale; it's wrong. Insulin resistance and general body inflammation are at the root of almost every chronic disease. We've got to talk about the soil, the microbiome, and what we call real food.
</details>

### 药品平权：打破价格垄断与推动非处方化革命

针对美国药品价格远高于欧洲的现状，Makary推行了“**最惠国待遇定价**”（Most Favored Nation Pricing: 确保美国政府购买药品的价格不高于其他发达国家的机制）。以GLP-1药物为例，其价格有望从1300美元降至149美元。此外，FDA正在通过简化**生物类似药**（Biosimilars: 在质量、安全性和疗效上与已获批生物药高度相似的廉价替代品）的审批流程，打破昂贵生物制剂的垄断地位，将研发周期从8年缩短至2.5年。

为了进一步降低成本，FDA正大规模推动处方药转向**非处方药**（OTC）。Makary认为，许多药物（如抗生素眼药水、前列腺药物）的处方化本质上是医疗家长主义的体现，增加了不必要的急诊访问和费用。通过让更多安全药物进入货架，利用市场竞争和价格透明度，可以有效绕过**药品福利管理人**（PBM: 介于保险公司、制药商和药房之间的中间商，常被指责推高药价）的暗箱操作，实现真正的药品降价。

<details>
<summary>Original English Source</summary>
It's been the great American ripoff. You buy a GLP-1 drug for $1,300 in the US and $88 in London. We want most favored nation status pricing. We are also cutting red tape for biosimilars, shortening the time frame from 8 years to 2.5 years. And why are a lot of drugs requiring a prescription? It's paternalism. We want to see a mass transition to more non-prescription drugs. When a drug is on the shelf, there is a price. It keeps prices in check and bypasses the crazy money games of PBMs. If your drug is safe and doesn't have abuse potential, it should be over the counter.
</details>

### 信任重建：核心疫苗清单与医学前沿展望

为了重建因疫情受损的公共卫生信任，FDA与**CDC**合作推出了“核心基本疫苗清单”。Makary解释说，美国现行的疫苗接种程序（0-18岁共72剂）是国际上的异类。通过筛选出约38剂的核心疫苗，FDA希望以更务实、更具透明度的方式与家长沟通，避免因“全盘接受或全盘拒绝”的极端立场导致接种率下降。他强调，医学界需要展现谦卑，承认科学中的不确定性。

展望未来，Makary对**基因疗法**、AI辅助诊断以及针对**PTSD**（创伤后应激障碍）和1型糖尿病的突破性疗法充满信心。FDA正在建立“优先凭证”制度，奖励那些针对国家重大卫生需求（如无需手术的癌症疗法）进行创新的公司。Makary总结道，FDA的现代化改革核心在于：以患者需求的速度移动，而非政府的速度。

<details>
<summary>Original English Source</summary>
The US vaccine schedule was an international outlier with 72 doses. We looked at 20 other countries and identified a list of core essential vaccines, about 38 doses. The idea is to increase vaccination rates by rebuilding public trust. American medicine needs to show some humility. Looking forward, I'm very optimistic about the pipeline—cures for type 1 diabetes, powerful treatments for ALS and PTSD. We are issuing priority vouchers for creative mechanisms that work. We have got to move at the speed that my patients demanded, not at government speed.
</details>